

CYTATION CORP  
Form 8-K  
August 04, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2005

Cytation Corporation

(Exact name of registrant as specified in its charter)

Delaware	00114800	16-0961436
(State of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

251 Thames Street, No. 8  
Bristol, Rhode Island 02809

(Address of principal executive office, including zip code)

(401) 254-8800

(Telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Items.

On April 8, 2005, the Company entered into a binding letter of intent with Evolve Oncology, Inc. ("Evolve") (Pink Sheets: "EVON") to effect a merger with Evolve pursuant to which the Company would have been the surviving corporation. In connection therewith, and in order to facilitate this transaction, the Board of Directors of the Company authorized a 3.75-for-1 forward stock dividend for stockholders of record on August 8, 2005.

THE COMPANY HAS TERMINATED ITS LETTER OF INTENT WITH EVOLVE AND REVOKED THE FORWARD STOCK DIVIDEND.

The Company will continue to seek a private operating company to effect a reverse merger or comparable transaction.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

CYTATION CORPORATION

By: /s/ Richard A. Fisher  
Richard A. Fisher  
Chairman and General Counsel

August 4, 2005